Skip to search formSkip to main contentSkip to account menu

Power mobility device, not coded by dme pdac or does not meet criteria

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Given that macroautophagy… 
Highly Cited
2019
Highly Cited
2019
Objective Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive type of GI tumour, and it possesses deregulated cellular… 
2019
2019
With a 5-year survival rate of only 8%, pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated… 
2019
2019
The present study aimed to determine the clinical significance and potential molecular mechanisms of C-C motif chemokine receptor… 
2019
2019
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, and early diagnosis and assessment may enhance… 
Highly Cited
2015
Highly Cited
2015
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible… 
2015
2015
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor survival despite current medical and surgical… 
2013
2013
The aim of the study was to evaluate the feasibility of a longitudinal non-invasive monitoring of rat pancreatic ductal… 
2013
2013
Pancreatic ductal adenocarcinoma (PDAC) remains a dismal disease with a poor prognosis and targeted therapies have failed in the…